Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.31 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28340397 | 1.00 | CYP4F2 (0.31) | CYP4F2CYP4A11EPHX1 | |
| SCHEMBL13406761 | 1.00 | CYP4F2 (0.31) | CYP4F2CYP4A11EPHX1 | |
| SCHEMBL6090748 | 1.00 | CYP4F2 (0.31) | CYP4F2CYP4A11EPHX1 | |
| SCHEMBL14252065 | 1.00 | CYP4F2 (0.31) | CYP4F2CYP4A11EPHX1 | |
| SCHEMBL5983615 | 0.97 | — | — | |
| SCHEMBL31474064 | 0.92 | — | — | |
| SCHEMBL1861367 | 0.85 | — | — | |
| SCHEMBL1791564 | 0.84 | CYP4F2 (0.37) | CYP4F2CYP4A11 | |
| SCHEMBL20104708 | 0.83 | — | — | |
| SCHEMBL28096467 | 0.82 | CYP4F2 (0.44) | CYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107848794-B | Method and device for storing and releasing hydrogen | 耶路撒冷希伯来大学伊萨姆研究开发有限公司 | 2021-08-24 | — | — | CN | disclosed |
| CN-113244117-A | Composition providing delayed release of active substances | 诺赛尔股份有限公司 | 2021-08-13 | — | — | CN | disclosed |
| EP-3350177-B1 | HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2021-07-07 | — | — | EP | disclosed |
| CN-107107019-B | Coated microcapsules | 诺赛尔股份有限公司 | 2021-06-18 | — | — | CN | disclosed |
| CN-107001979-B | Coated microcapsules | 诺赛尔股份有限公司 | 2021-05-28 | — | — | CN | disclosed |
| CN-107249545-B | Composition providing delayed release of active substances | 诺赛尔股份有限公司 | 2021-05-25 | — | — | CN | disclosed |
| CN-106999896-B | Coated microcapsules | 诺赛尔股份有限公司 | 2020-10-30 | — | — | CN | disclosed |
| EP-2534132-B1 | SUBSTITUTED PYRROLIDINE-2-CARBOXAMIDES | HOFFMANN LA ROCHE (CH) | 2017-04-26 | — | — | EP | disclosed |
| WO-2017049068-A1 | HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2017-03-23 | — | — | WO | disclosed |
| US-20170081317-A1 | HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2017-03-23 | — | — | US | disclosed |
| EP-2340021-B1 | SUBSTITUTED PYRROLIDINE-2-CARBOXAMIDES | HOFFMANN LA ROCHE (CH) | 2012-11-07 | — | — | EP | disclosed |
| WO-2011098398-A1 | SUBSTITUTED PYRROLIDINE-2-CARBOXAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-08-18 | — | — | WO | disclosed |
| EP-2340021-A1 | SUBSTITUTED PYRROLIDINE-2-CARBOXAMIDES | F. Hoffmann-La Roche AG (CH) | 2011-07-06 | — | — | EP | disclosed |
| US-20100152190-A1 | Substituted Pyrrolidine-2-Carboxamides | F. HOFFMANN-LA ROCHE AG (CH) | 2010-06-17 | — | — | US | disclosed |
| WO-2010031713-A1 | SUBSTITUTED PYRROLIDINE-2-CARBOXAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-03-25 | — | — | WO | disclosed |
| US-20100075948-A1 | Substituted Pyrrolidine-2-Carboxamides | DING QINGJIE | 2010-03-25 | — | — | US | disclosed |
| US-20070093536-A1 | Target protein of antidiabetic and novel antidiabetic insuful corresponding thereto | REVERSE PROTEOMICS RESEARCH INSTITUTE CO., LTD. (JP) | 2007-04-26 | — | — | US | disclosed |
| EP-1713771-A1 | NEW CRYSTALLINE FORM OF PERINDOPRIL | LEK Pharmaceuticals D.D. (SI) | 2006-10-25 | — | — | EP | disclosed |
| EP-1698696-A1 | TARGET PROTEIN OF ANTIDIABETIC AGENT AND NOVEL ANTIDIABETIC AGENT INSUFUL CORRESPONDING THERETO | Reverse Proteomics Research Institute Co., Ltd (JP) | 2006-09-06 | — | — | EP | disclosed |
| WO-2005068425-A1 | NEW CRYSTALLINE FORM OF PERINDOPRIL | LEK PHARMACEUTICALS D.D. (SI) | 2005-07-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170081317-A1 | HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | CYP4F2 2828/4885CYP4A11 1871/4885EPHX1 2027/4885 |
| US-20100152190-A1 | Substituted Pyrrolidine-2-Carboxamides | ARG2, CCNY, PYCR1 | CYP4F2 1283/4885CYP4A11 3282/4885EPHX1 3073/4885 |
| US-20070093536-A1 | Target protein of antidiabetic and novel antidiabetic insuful corresponding thereto | IGFBP4, IGF2BP1, INSRR | CYP4F2 2155/4885CYP4A11 3430/4885EPHX1 4225/4885 |
| US-20100075948-A1 | Substituted Pyrrolidine-2-Carboxamides | ARG2, CCNY, PYCR1 | CYP4F2 1283/4885CYP4A11 3282/4885EPHX1 3073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.